Business Standard

Friday, December 20, 2024 | 05:14 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Top headlines: L&T Q3 net falls; nod for Bharat Bio's intranasal dose trial

Business Standard brings you the top headlines on Friday

Bharat Biotech, Covaxin
Premium

Photo: Shutterstock

BS Web Team New Delhi
DCGI gives permission to Bharat Biotech for intranasal booster dose trials

India's drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for its intranasal Covid vaccine as booster dose on participants who have been previously inoculated with SARS-CoV 2 vaccines.

India is yet to approve the use of intranasal COVID-19 vaccine BBV154 developed by the Hyderabad-based company. Read more

India to export BrahMos missiles to Philippines, signs $374-mn deal

India got its first ever export order for BrahMos missiles on Friday when the Philippines' Defence Ministry signed $374 million contract with BrahMos Aerospace Private Limited to supply

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in